A Review of Patient-Reported Outcome Measures in Childhood Cancer

Madeline R. Horan 1, Jin-ah Sim 2, Kevin R. Krull 1,3, Justin N. Baker 4 and I-Chan Huang 1,*

1 Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
2 School of AI Convergence, Hallym University, Chuncheon 200160, Korea
3 Department of Psychology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
4 Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
* Correspondence: i-chan.huang@stjude.org; Tel.: +1-(901)-595-8369

Abstract: Patient-reported outcomes (PROs) are used in clinical work and research to capture the subjective experiences of childhood cancer patients and survivors. PROs encompass content domains relevant and important to this population, including health-related quality-of-life (HRQOL), symptoms, and functional status. To inform future efforts in the application of PRO measures, this review describes the existing generic and cancer-specific PRO measures for pediatric cancer populations and summarizes their characteristics, available language translations, content coverage, and measurement properties into tables for clinicians and researchers to reference before choosing a PRO measure that suits their purpose. We have identified often unreported measurement properties that could provide evidence about the clinical utility of the PRO measures. Routine PRO assessment in pediatric cancer care offers opportunities to facilitate clinical decision-making and improve quality of care for these patients. However, we suggest that before implementing PRO measures into research or clinical care, the psychometric properties and content coverage of the PRO measures must be considered to ensure that PRO measures are appropriately assessing the intended construct in childhood cancer patients.

Keywords: childhood cancer survivors; chronic health conditions; health-related quality-of-life; symptoms

1. Introduction

With advances in cancer treatments, the survival rate of children and adolescents with cancer is now over 80% in many high-income countries and 37% globally [1]. However, childhood cancer patients and survivors may experience many different acute and chronic physical and psychological side effects (e.g., anemia, constipation, fatigue, pain) and late effects (e.g., cognitive impairment, neuropathy, hearing loss, cardiac, pulmonary, and endocrine disorders) from their cancer diagnosis and associated treatments [2]. Over the course of their cancer journey from diagnosis to survivorship, these effects are likely to impact the patient’s/survivor’s health-related quality-of-life (HRQOL), differentially for patients with different diagnoses and treatments [3]. Overall, patients and survivors report poorer HRQOL and daily functioning [4,5] and increased symptom burden [6] compared to their siblings and the general population. The subjective nature of many of these acute side effects and late effects are well-suited to be assessed via patient-reported outcome (PRO) measures. PROs is an umbrella term to capture the concepts of HRQOL, functional status, subjective well-being, and physical, somatic, and psychological symptoms [7].

The subjective experience of childhood cancer patients and survivors is an important outcome to consider in survivorship research, patient and survivorship care, and clinical trials. As of 2009, the US FDA requires that all clinical trials use PRO measures as an efficacy endpoint [8], but only 21% of clinical trials conducted from 2007 to 2020 that included adolescents and young adults with cancer collected PRO measures as a secondary or exploratory endpoint [9]. PRO measures have been shown to better predict survival than...
clinician-assessed performance and biomarkers in adult cancer trials [10]. In pediatric cancer survivors, PRO measures of symptom burden have predicted the progression of late effect CHCs [11], and comorbid symptoms have been shown to affect HRQOL [12–14] and adverse health outcomes [15–17]. Even though PRO measures play an important role in pediatric oncology, clinicians report barriers to using these measures in their practices, such as the lack of training to administer, score, and interpret PROs, the lack of clinically meaningful cutoffs to aid in interpretation, and uncertainty about the validity of various PRO measures [18,19].

There have been published systematic reviews of HRQOL measures for childhood cancer patient and survivor populations [3,20–25], but these review studies tend to summarize the measurement properties rather than evaluate the content coverage of PRO measures and identify specific measurement properties of PRO measures that require further improvement for clinical use. This review describes the extant PRO measures for pediatric cancer populations and summarizes their characteristics, content coverage, and measurement properties. The PRO measures that we selected are for patients/survivors younger than 21 years of age, but the clinical application (e.g., predictive validity for late effects) can be extended to adult survivors of childhood cancer. In this review, we aimed to identify measurement properties of PRO measures that are relevant to clinical practice, discuss the ways in which these measures and their clinical application can be improved, and provide recommendations for future implementation of PRO measures.

2. Materials and Methods

In 2019, we searched PubMed for existing review articles of PRO measures to identify existing measures (see Figure 1 for a flow diagram of PRO measure selection). Then, we searched PubMed for additional PRO measures. For each PRO measure, we searched PubMed with the name and abbreviations of the measure (e.g., “Pediatric Quality of Life Inventory” OR “PedsQL”) and the following search terms: (cancer [title/abstract] OR tumor [title/abstract] OR tumors [title/abstract] OR oncolog* [title/abstract] OR chemoth* [title/abstract] OR “bone marrow transplantation” [title/abstract] OR “stem cell transplantation” [title/abstract]) AND (pediatric [title/abstract] OR paediatric [title/abstract] OR child [title/abstract] OR childhood [title/abstract] OR children [title/abstract] OR youth [title/abstract] OR adolescent* [title/abstract] OR “young adult” [title/abstract]). Articles were considered for inclusion if the full text was available, the article and PRO measure were available in English, the population was childhood cancer patients and/or survivors, and the study sample was less than 21 years old. Conference abstracts and grey literature were excluded. The article abstracts were reviewed for psychometric and clinical application information. Key articles about the psychometric properties were selected if the article was from a peer-reviewed journal, reported at least one of the psychometric properties from the COSMIN user manual [26–28], and the measure was externally validated with a sample different from the one used in the original development of the PRO measure. PRO measures with at least five key published articles were retained in this review to provide a summary of the most used and validated PRO measures. The PRO measures were then categorized as a generic or cancer-specific measure. The full and abbreviated names of each included PRO measure are provided in Table 1.

We then identified the original development articles, the article with the first or most representative application in childhood cancer patients/survivors, and the PRO measure’s website (if available) for each PRO measure. The characteristics of the PRO measure and the sample of childhood cancer patients/survivors from the first or most representative application of the PRO in this population were extracted (Supplementary Table S1). In addition, two different reviewers extracted and categorized the content coverage of each PRO measure based on existing classifications of content domains [20,21,29,30] (Tables 2 and 3). Psychometric properties based on the COSMIN guidelines [26,27] were extracted from key validation articles (Table 4 and Supplementary Table S2).
Table 1. Abbreviations of PRO assessment tool names.

| Abbreviation | Full Name |
|--------------|-----------|
| **Generic measures** | |
| BDI | Beck Depression Inventory |
| CDI | Children’s Depression Inventory |
| CHIP | Child Health and Illness Profile |
| CHQ | Child Health Questionnaire |
| DCGM | DISABKIDS Chronic Generic Module |
| FPSR | Faces Pain Scale-Revised |
| HADS | Hospital Anxiety and Depression Scale |
| HUI | Health Utilities Index |
| KIDSCREEN | KIDSCREEN |
| KINDL | KINDL |
| PedsQL-Core | Pediatric Quality of Life Inventory Core Module |
| PedsQL-MFM | Pediatric Quality of Life Inventory Multidimensional Fatigue Module |
| PPS | Play Performance Scale |
| PROMIS | Patient-Reported Measurement Information System |
| RCMAS | Revised Children’s Manifest Anxiety Scale |
| STAIC | State-Trait Anxiety Inventory for Children |
| TNO-AZL | TNO AZL Quality of Life |
| **Cancer-specific measures** | |
| BASES | Behavioral Affective and Somatic Experiences Scale |
| ChIMES | Children’s International Mucositis Evaluation Scale |
| FS | Fatigue Scale |
| MMQOL | Minneapolis-Manchester Quality of Life |
| MSAS | Memorial Symptom Assessment Scale |
| OMDQ | Oral Mucositis Daily Questionnaire |
| Pain Squad App | Pain Squad Application |
| PCQL-32 | Pediatric Cancer Quality of Life Inventory-32 |
| PEDQOL | Quality of Life in Children and Adolescents with Cancer |
| PedsFACT-Brs | Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivors |
| PedsQL-Brain Tumor | Pediatric Quality of Life Inventory Brain Tumor Module |
| PedsQL-Cancer | Pediatric Quality of Life Inventory Cancer Module |
| PeNAT | Pediatric Nausea Assessment Tool |
| POQOLS | Pediatric Oncology Quality of Life Scale |
| SSPedi | Symptom Screening in Pediatrics Tool |
| TRSC-C | Therapy-Related Symptom Checklist-Children |

Figure 1. Flow diagram of PRO measure selection.
Table 2. Content coverage for generic PRO measures used in pediatric cancer populations by major domains and subdomains.

| Domain                          | BD1 | CDI | CHIP | CHQ | DCGM | FPSR | HADS | KIDSSCREEN | KINDL | PedsQL-Core | PedsQL-MFM | PPS | PROMIS | RCMAS | STAIC | TNO-AZL |
|--------------------------------|-----|-----|------|-----|------|------|------|------------|-------|-------------|------------|-----|--------|-------|-------|--------|
| Physical health                |     |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |
| Function                        | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          | X   |        |       |       |        |
| Symptoms                        | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          | X   |        |       |       |        |
| Functional independence        | X   |     |       | X   | X    | X    | X    | X          |       | X           |            | X   |        |       |       |        |
| Psychological health/functioning|     |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |
| Body image                     | X   |     |       |     |      |      |      |            |       |             |            |     |        |       |       |        |
| Self-esteem                    | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          |     |        |       |       |        |
| Positive psychological function| X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          |     |        |       |       |        |
| Cognitive                       | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          |     |        |       |       |        |
| Emotional distress              | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          |     |        |       |       |        |
| Social health                  |     |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |
| Relationship                   | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          |     |        |       |       |        |
| Function                       | X   |     | X    | X   | X    | X    | X    | X          |       | X           | X          |     |        |       |       |        |
| School functioning/social behavior|      |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |
| General health perception      |     |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |
| Cancer diagnosis/treatment     |     |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |
| Other                          |     |     |      |     |      |      |      |            |       |             |            |     |        |       |       |        |

Bolded domains are broad content categories and non-bolded domains are subcategories within those broad domains. Content domain categories based on previous reviews [20,30]. Presence of reported content area indicated with an X. See Table 1 for full names of PRO assessment tools. See Supplementary Table S4 for references for each PRO measure; * Activity, acute major disorders, acute minor disorders, ambulation, dexterity, effect of pain on sleeping, hearing, limitations of activity, long-term medical, long-term surgical, loss of libido, mobility, motor functioning, movement and balance, physical activity, physical function and role restriction, physical function-mobility, physical function-upper extremity, physical functioning, psychological stress experience, physical well-being, problems/limitations concerning general physical functioning/complaints, recurrent disorders, role/social-physical, sleep, sleep disturbance, speech, strength impact, vision; ** Abdominal pain, affective, amount of diarrhea, amount of mouth and throat pain, amount of pain medication received, appetite, appetite loss, asthma impact, bleeding/hematuria, bodily pain, bone marrow toxicity/neuropathy, change in health, comfort, constipation, diarrhea, eating more/less, fatigue, fertility, headache, inefficaciveness, lack of energy, lung problems, malaise, mouth sores, mucositis, nausea, neurotoxicities, not able to function, oropharyngeal pain, pain; * Activity, acute major disorders, ambulation, dexterity, effect of pain on sleeping, hearing, limitations of activity, long-term medical, long-term surgical, loss of libido, mobility, motor functioning, movement and balance, physical activity, physical function and role restriction, physical function-mobility, physical function-upper extremity, physical functioning, psychological stress experience, physical well-being, problems/limitations concerning general physical functioning/complaints, recurrent disorders, role/social-physical, sleep, sleep disturbance, speech, strength impact, vision; }
family, family dynamics, family involvement, friends, interactions (quality of patient-parent interaction, quality of patient-staff interaction, quality of parent-staff interaction, parent in room), interpersonal problems, parent-child relationship, parent relation & home life, parental emotional impact, parental time impact, peer, peer influences, physician/nurse communication, resilience, significant others, social, social withdrawal, social/family well-being, teachers; \textsuperscript{b} Achievement, anhedonia, family activities, family cohesion, interpersonal problems related to cancer and biomedical treatment, problems/limitations in social contacts with parents and peers, social exclusion, social functioning, social functioning (inter-personal functioning in peer relations), social functioning friends, social inclusion, threats to achievement; \textsuperscript{c} Academic performance, school environment, work performance; \textsuperscript{d} General health perceptions, global distress, global health; \textsuperscript{e} Brain tumor survivor-specific concerns, disease and treatment-related symptoms, disease specific modules, procedural anxiety, reaction to current medical treatment, treatment anxiety, worry (about cancer and its treatment). \textsuperscript{f} Financial resources; \textsuperscript{g} Play for functional status.

Table 3. Content coverage for generic PRO measures used in pediatric cancer populations by major domains and subdomains.

| Physical health | BASES | ChIMES | FS | MMQSL | MSAS | OMDQ | Pain Squad App | PCQL-32 | PEDQOL | PedsFACT-Brs | PedsQL-Brain Tumor | PedsQL-Cancer | PSNAT | PQQOLS | SS-Pedi | TRSC-C |
|----------------|-------|--------|----|-------|------|------|----------------|--------|---------|--------------|-----------------|-------------|--------|--------|--------|--------|
| Function \textsuperscript{b} | X | X | X | X | X | X | X | X | X |
| Symptoms \textsuperscript{b} | X | X | X | X | X | X | X | X | X |
| Functional independence \textsuperscript{b} | X | X | X | X | X | X | X | X | X |

Psychological health/functioning

| Positive psychological function | X | X | X | X | X | X | X | X | X | X |
| Cognitive \textsuperscript{b} | X | X | X | X | X | X | X | X | X | X |
| Emotional distress \textsuperscript{s} | X | X | X | X | X | X | X | X | X | X |

Social health

| Relationship \textsuperscript{f} | X | X | X | X | X | X | X | X | X | X |
| School functioning/social behavior \textsuperscript{f} | X | X | X | X | X | X | X | X | X | X |

General health perception \textsuperscript{f0}

Cancer diagnosis/treatment \textsuperscript{f}

Other

Bolded domains are broad content categories and non-bolded domains are subcategories within those broad domains. Content domain categories based on previous reviews \([20,30]\). Presence of reported content area indicated with an X. See Table 1 for full names of PRO assessment tools. See Supplementary Table S4 for references for each PRO measure; \textsuperscript{a} Activity, acute major disorders, acute minor disorders, ambulation, dexterity, effect of pain on sleeping, hearing, limitations of activity, long-term medical, long-term surgical, loss of libido, mobility, motor functioning, movement and balance, physical activity, physical function and role restriction, physical function-mobility, physical function-upper extremity, physical functioning, physical limitation, physical stress experience, physical well-being, problems/limitations concerning general physical functioning/complaints, recurrent disorders, role/social-physical, sleep, sleep disturbance, sleep, speech, strength impact, vision; \textsuperscript{b} Abdominal pain, affective, amount of diarrhea, amount of mouth and throat pain, amount of pain medication received, appetite, appetite loss, asthma impact, bleeding/hematuria, bodily pain, bone marrow toxicity/neuropathy, change in health, comfort, constipation, diarrhea, eating more/less, fatigue, fertility, headache, ineffectiveness, lack of energy, lung problems, malaise, mouth sores, mucositis, nausea, neurotoxicities, not able to function, oropharyngeal, pain, pain intensity, pain quality-affective, pain quality-sensory, pain-behavior, pain-interference, physical discomfort, physical severity, physical symptoms, psychosocial/central nervous system, respiratory/other, skin problems, sleep-related disturbance, sleep-related impairment, sleep/rest fatigue, somatic distress, somatic preoccupation, symptom severity: nutrition related, throwing up, tingly hands/feet, tired, weight loss; \textsuperscript{c} Autonomy, drooling-pooling of saliva, effect on drinking, effect on eating, effect on talking, effect on swallowing, homely safety and health, independence, individual risks, functional status in the activities of daily living, problems/limitations concerning independent daily functioning, self-care; \textsuperscript{d} Appearance: presence of ulcers, body image, changes to how face/body look, perceived physical appearance; \textsuperscript{e} body image (serves as an indicator of self-esteem), self-esteem, self-perception, sense of failure, self-hate, self-accusations, self-punitive wishes; \textsuperscript{f} Engagement-persistence, life satisfaction, liveliness, meaning and purpose, positive affect, satisfaction with health, engagement-curiosity, lack of satisfaction, outlook on life, positive mood, satisfaction; \textsuperscript{g} Aggressive, complaining/demanding, cooperation/compliance (oral medications,
mouth care, bath/sitz bath, Hickman line care, vital signs/physical examination, eating/drinking, exercise/physical therapy, overall cooperation), regressed behavior, self-stimulatory behavior, talkative/engaging, crying spells, defensiveness, emotional distress-related experiences, emotional distress-depressive symptoms, fearful/overprotective, guilt feeling, irritability, mood swings, anxiety, worry, oversensitivity, altered mood, anxiety, cheerful/friendly, emotional discomfort, energetic distress, emotional distress-anger, emotional functioning, emotional well-being, emotional well-being and illness experiences, feelings (disappointed/sad, scared/worried, angry/frustrated, mental health, mood, negative mood, physiological anxiety.

Psychologic Functioning: This scale encompasses emotional functioning and includes items that involve emotional distress and worry, psychological functioning (emotional distress), psychological functioning (emerges emotional functioning), psychological severity, frequency, and distress, psychological well-being, state anxiety, worry; Bullying, community, family, family dynamics, family involvement, friends, interactions (quality of patient-parent interaction, quality of patient-staff interaction, quality of parent-child interaction, parent in room), interpersonal problems, intimate relations, parent relation & home life, parent emotional impact, peer influences, physician/nurse communication, resilience, significant others, social, social withdrawal, social/family well-being, teachers; Achievement, anhedonia, family activities, family cohesion, interpersonal problems related to cancer and biomedical treatment, problems/limitations in social contacts with parents and peers, social exclusion, social functioning, social functioning (inter-personal functioning in peer relations), social functioning friends, social inclusion, threats to achievement; Academic performance, school environment, work performance; General health perceptions, global distress, global health; Brain tumor survivor-specific concerns, disease and treatment-related symptoms, disease specific modules, procedural anxiety, reaction to current medical treatment, treatment, treatment anxiety, worry (about cancer and its treatment).

Table 4. Presence of measurement properties tested in PRO measures for pediatric cancer populations.

| PRO Measure | Structural Validity | Internal Consistency | Reliability | Construct Validity/ Known-Group Validity | Cross-Cultural Validity/ Measurement Invariance | Criterion Validity | Responsiveness | Predictive Validity | Cut Points/ MID | Responsivity | Score Calculation |
|-------------|---------------------|---------------------|-------------|-----------------------------------------|-----------------------------------------------|-------------------|----------------|-------------------|----------------|-------------|------------------|
| BDI pedG, pedO | pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | BDI-II: sum score, BDI-Y: T scores (standardized based on age and gender) |
| CDI pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Sum score |
| CHIP pedG, pedO | pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Standardised scores with mean of 20 and standard deviation of 10 or mean of 50 and standard deviation of 10 |
| CHQ pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Sum score, then converted to 0–100 scale |
| DCM pedG, pedO | pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Sum score, then converted to 0–100 scale |
| FPSR pedG | pedC | pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Single item score 0–10 |
| HADS pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Utility function from preference scores based on Neumann-Morgenthau utility theory, VAS, then SG, 0 (dead) to 1 (perfect health) |
| KINDL pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | T-values based on Rasch person parameters |
| KDSC screener pedG, pedO | pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Mean score for psychosocial health scale, physical health scale, and total score; transforms scores to 0–100 scale |
| PedsQL-Core pedG | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Mean score for general fatigue scale, sleep/rest fatigue scale, cognitive fatigue scale, and total score; transforms scores to 0–100 scale |
| PedsQL-MFM pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | pedO | Single item, 0–10 in increments of 10 |
### Table 4. Cont.

| PRO Measure | Structural Validity | Internal Consistency | Reliability | Construct Validity/ Known-Group Validity | Cross-Cultural Validity/ Measurement Invariance | Criterion Validity | Responsiveness | Predictive Validity | Cut Points/ MIDs | Response Shift | Score Calculation |
|-------------|---------------------|----------------------|-------------|------------------------------------------|-----------------------------------------------|-------------------|----------------|-------------------|-----------------|---------------|------------------|
| PROMIS      | PedO                | PedO                 | PedO        | PedO                                     | PedO                                          | PedO              | PedO          | PedO              | PedO            | PedO          | T-score with mean of 50 and standard deviation of 10. In most cases 50 equals the mean in the U.S. general population. |
| RCMAS       | PedO                | PedO                 | PedO        | PedO                                     | PedO                                          | PedO              | PedO          | Sum scores       |                |               |                  |
| STAAR       | PedO                | PedO                 | PedO        | Sum scores                               |                                               |                   |               |                   |                |               |                  |
| TN20-A2L    | PedO                | PedO                 | PedO        | Sum score then converted to 0–100 score, TACQOL no total score, just summed subdomain scores |                                               |                   |               |                   |                |               |                  |

**Cancer-specific**

| BASES       | PedO                | PedO                 | PedO        | PedO                                     | PedO                                          | PedO              | PedO          | Sum scores       |                |               |                  |
| CHMDS       | PedO                | PedO                 | PedO        | Sum scores                               |                                               |                   |               |                   |                |               |                  |
| PS          | PedO                | PedO                 | PedO        | Sum scores                               |                                               |                   |               |                   |                |               |                  |
| MMQL        | PedO                | PedO                 | PedO        | Sum scores                               |                                               |                   |               |                   |                |               |                  |
| ARAS        | AduO, PedO          | PedO                 | PedO        | Mean score                               |                                               |                   |               |                   |                |               |                  |
| OMDQ        | PedO                | PedO                 | PedO        | Total score has not been validated—examine items separately                                    |                                               |                   |               |                   |                |               |                  |
| Pain Squad App | PedO                | PedO                 | PedO        | PedO                                     | PedO                                          |                   |               |                   |                |               |                  |
| PCQL-M      | PedO                | PedO                 | PedO        | Scores converted to T-score then mean of 50 and standard deviation of 10                      |                                               |                   |               |                   |                |               |                  |
| PEDQOL      | PedO                | PedO                 | PedO        | Scores converted to T-score then mean of 50 and standard deviation of 10                      |                                               |                   |               |                   |                |               |                  |
| PedFACT-Brs | PedO                | PedO                 | PedO        | Sum, multiply by number of items in subscale, divide by number of items answered = symptom index score |                                               |                   |               |                   |                |               |                  |
| PedQL-Brain Tumor | PedO | PedO | PedO | Mean score for cognitive problems scale, pain and hurt scale, movement and balance scale, procedural anxiety scale, nausea scale, worry scale, and total score; transform scores to 0–100 scale | | | | | | | |
| PedQL-Cancer | PedO                | PedO                 | PedO        | Mean score for pain and hurt scale, nausea scale, procedural anxiety scale, treatment anxiety scale, worry scale, cognitive problems scale, perceived physical appearance scale, communication scale, and total score; transform scores to 0–100 scale |                                               |                   |               |                   |                |               |                  |
| PeNAT       | PedO                | PedO                 | PedO        | 1–4 from single item                      |                                               |                   |               |                   |                |               |                  |
| PCQLS       | PedO                | PedO                 | PedO        | Sum scores                               |                                               |                   |               |                   |                |               |                  |
| SSPeds      | PedO                | PedO                 | PedO        | Sum scores                               |                                               |                   |               |                   |                |               |                  |
| TOSC-C      | PedO                | PedO                 | PedO        | Sum score                                |                                               |                   |               |                   |                |               |                  |

Psychometric property categories based on COSMIN guidelines [26,27]. PedG = Pediatric general (non-oncology) sample, PedO = Pediatric oncology patient/survivor sample, AduO = Adult oncology sample. See Table 1 for full names of PRO assessment tools. See Supplementary Table S4 for references for each PRO measure.
3. Results

3.1. Generic PRO Measures

Seventeen generic PRO measures were identified through our literature search (see Supplementary Table S1 for study characteristics). The majority of the generic PRO measures use a Likert-type response scale. The HUI, PPS, and RCMAS all use binary response scales (e.g., yes/no). The CHIP and FPSR use a visual response scale (e.g., cartoon-depicted faces of different emotions for the patient to choose from). The number of items in each PRO measure varies greatly—from 1 visual response scale item in the PPS and FPSR to 602 items in all of the item banks of the PROMIS. PROs can be assessed through two primary approaches: health profile and health preference methods. Health profile measures provide scores for a patient’s perception on a variety of different PRO domains (e.g., physical functioning, psychological functioning) [31]. In contrast, health preference measures provide a single summary score of the patient’s perception of a PRO construct that is weighted by the general public’s valuation of different health states [31]. All but one generic PRO measure, the HUI, were created using the health profile approach. The HUI was developed to assess health status using the health preference approach. Many of the self-reported PRO measures are appropriate for children 8–17.9 years of age; some measures are appropriate for adolescents/young adults (e.g., BDI, HADS); and few measures (e.g., PPS, PedsQL-Core, KINDL) are available for younger children (e.g., 2–4.9 years of age) via parent-proxy reporting. Most measures have a recall period of at least one week, but some (e.g., state version of the STAIC, FPSR) are used for assessing the respondent’s current PRO status. Most of the generic PRO measures are available in various languages (see Supplementary Table S3 for available language translations).

These generic PRO measures have been widely used in studies of childhood cancer patients/survivors. For each measure, we identified the first or most representative study to administer the measure to either childhood cancer patients or survivors and summarized the sample characteristics in Supplementary Table S1. Twelve studies included cancer patients as the study population, and five studies assessed survivors. Most of the studies assessed adolescents, although a few studies measured PROs in children as young as 11 months (e.g., HUI). Many of the studies were conducted in the US, but there are also studies from Australia, Sweden, Canada, Austria, and the Netherlands. Most studies assessed children with a variety of cancer diagnoses, but a few included only children with leukemia, only children with CNS tumors, or only children with solid tumors.

3.2. Cancer-Specific PRO Measures

Sixteen cancer-specific PRO measures were identified through our search. Most employ a Likert-type response scale, but the ChIMES, OMDQ, Pain Squad App, and PeNAT all used visual scales. The number of items range from 6 to 48 across the cancer-specific measures. All of the cancer-specific PRO measures are health profile measures. Most measures are available for children 8–17.9 years of age, some for children 5–7.9 years old, and few for children under 5 years old. Most measures are available in both self-reported and proxy-reported forms. Many of the measures assess current PRO status of the patient/survivor, but some measures have a recall period of 24 h (e.g., OMDQ), one week (e.g., MSAS, PedsQL acute modules), two weeks (e.g., POQOLS), or one month (e.g., PCQL-32, PedsQL chronic modules).

The majority of the cancer-specific PRO measures were developed exclusively for childhood cancer patients/surivivors, with the exception of the MSAS and OMDQ, which were first developed for adult cancer patients/survivors and then validated in pediatric cancer populations. In the studies that applied these cancer-specific measures to pediatric cancer patients/survivors, four assessed PROs in survivors via the PCQL-32, PEDQOL, PedsFACT-Brs, and PedsQL-Cancer, and the rest measured PROs in cancer patients currently undergoing treatment or newly off treatment. Most studies included both children and adolescents. All but four studies were conducted in the US. Three studies were conducted in Canada and one in Germany. All the studies assessed patients and/or sur-
vivors with a variety of cancer diagnoses except the brain tumor-specific measures (i.e., PedsFACT-Brs and PedsQL-Brain Tumor).

3.3. Measurement Properties

To better understand the limitations of the extant PRO measures, we examined their content coverage, scoring methods, and psychometric properties (e.g., cutpoints and minimally important differences [MIDs], responsiveness and predictive validity, and response-shift effects).

3.3.1. Content Coverage

The content coverage of the generic PRO measures is listed in Table 2. The framework used for organizing the content domains is based on previously published reviews [20,30]. The generic PRO measures cover a wide variety of content domains. The most common domains are physical functioning, physical symptoms, and emotional distress. Body image is assessed by only two measures (i.e., BDI and PedsQL-Core). The measures that cover the greatest range of content areas across physical, psychological, and social domains are the BDI (9 areas), CHIP (11 areas), and CHQ (9 areas).

Many of the cancer-specific measures also cover physical and social health domains, but do not commonly assess domains of psychological health (see Table 3). Behavior is only assessed through the BASES. Of the cancer-specific measures, the most content domains are covered by the BASES (6 areas), MMQL (7 areas), and PEDQOL (6 areas). Five of the measures, the PCQL-32, PedsFACT-Brs, PedsQL-Brain Tumor, PedsQL Cancer, and POQOLS, cover PRO content related to the cancer diagnosis and treatment procedures (e.g., brain tumor survivor-specific concerns, disease and treatment-related symptoms, disease specific modules, procedural anxiety, reaction to current medical treatment, treatment anxiety).

3.3.2. Scoring Methods

Most of the extant PRO measures employ a summation method to calculate PRO domain scores (e.g., PedsQL-Core, BASES). Recent PRO measures (e.g., PROMIS) use more rigorous methods (e.g., Item Response Theory or Confirmatory Factor Analysis weights) by taking into account possible differences in the relationship between the construct of interest and individual items [32–34].

3.3.3. Psychometric Properties

Psychometric criteria were not fully tested in extant PRO measures. The majority of the generic and cancer-specific PRO measures have reported internal consistency, reliability, and construct or known-group validity. Many of the generic PRO measures also reported structural validity and cross-cultural validity or measurement invariance. According to the COSMIN guidelines, criterion validity requires a gold standard measure to be associated with the PRO measure, and the guidelines also indicate that there are no gold standard PRO measures [26]. Alternatively, a correlation between a short-form version and long-form version of the same PRO measure can be considered evidence for criterion validity [26], and this was reported for only two of the generic PRO measures (i.e., the BDI and KINDL) and none of the cancer-specific measures. Fewer psychometric properties related to clinical parameters (i.e., clinical validity) were assessed and/or reported for the cancer-specific measures compared to the generic PRO measures. These clinically relevant measurement properties that may facilitate clinical decision-making include cutpoints, MIDs, responsiveness to change, and response-shift effects.

Only four of the PRO measures (i.e., BDI, KIDSCREEN, PedsQL-Core, PROMIS) have established severity cutpoints and/or MIDs, and these properties are not available for any cancer-specific measures. Responsiveness to change, predictive validity, and response-shift effects are all uncommonly described in the literature addressing psychometric properties of existing PRO measures. All three of these properties are clinically useful for communication about the disease progression with patients and caregivers, facilitating decision-making
about changing the treatment regimen, and tracking health status changes (e.g., disease progression, changes due to interventions) over time. Responsiveness to change was examined for seven of the generic PRO measures and seven of the cancer-specific PRO measures. Only one study examined response-shift effects using the PedsQL-Core [35].

4. Discussion

Concurrently capturing the content domains that are important to childhood cancer patients and examining the PRO measures’ psychometric properties is vitally important when implementing PRO measures into clinical care [29]. Our review examined both of these attributes of existing PRO measures in childhood cancer survivors. The extant PRO measures for this population are varied in their content coverage and reported measurement properties. Physical functioning, physical symptoms, and emotional distress are common content areas in the existing PRO measures. School functioning and self-esteem are content domains that are critically important to pediatric populations especially among adolescents, and they are not covered by any cancer-specific PRO measure but are available with some generic PRO measures. None of the PRO measures are comprehensive in their content coverage. Additionally, none of the existing PRO measures identified through our search assess other content domains relevant to childhood cancer patients and survivors, including cancer-related stigma, infertility concerns, chronic symptoms, future health expectations, and caregiver quality-of-life [29].

Some previous review studies have identified the measurement properties of extant PRO measures [22,25], and other reviews have identified uncertainty about the clinical validity of PRO measures as an implementation barrier [18,19]. To bridge these review topics, we have identified often unreported measurement properties that could provide evidence about the clinical utility of the PRO measures including clinical anchors, clinically meaningful cutpoints and MIDs, responsiveness, predictive validity, response-shift effects, and cross-cultural validity. Assessing clinical validity based on meaningful clinical anchors or known-groups in the development and validation of PRO measures is often under-reported. If known-group validity was assessed, most of the studies used extant measures to compare cancer patients/survivors (or cancer diagnoses) to healthy controls or siblings. However, most studies did not consider treatment modality data, objectively-evaluated physical or neurocognitive performance, or severity graded late effects or CHCs as clinical anchors for assessing clinical validation, which are known to affect PROs in childhood cancer patients and survivors [36,37]. Using and reporting on these clinical anchors may enhance the clinical utility of PRO measures.

In addition, clinicians report the lack of clinically meaningful cutpoints and MIDs as another application barrier [18,19]. Only four of the extant generic PRO measures included in our review established cutpoints and/or MIDs. Clinicians may want to use cutpoints to aid in the interpretation of the PRO score. For example, cutpoints are useful in a screening measure to identify patients or survivors at high levels of reported adverse health outcomes. MIDs are useful for clinicians to identify meaningful intraindividual change in their patients. Clinical anchors (e.g., change in number of fatigue episodes, change in performance on a cognitive task) can be used to establish clinical interpretability of PRO scores [8]. MIDs should be calculated based on patient-centered and/or clinically based anchors so that differences in scores that reach this MID threshold have patient-centered meaning. MIDs are typically estimated with clinical anchors or distribution-based methods, but there are some novel approaches to estimating MIDs, such as scale judgment [38] and bookmarking [39], that require patients, family members, and health care professionals to judge different health scenario vignettes. Then IRT methods are used to identify the MIDs from their judgments. Similar to traditional clinical anchors, these are patient-centered approaches to establishing MIDs, but they also incorporate judgements from multiple perspectives.

Other under-reported measurement properties related to clinical validity are responsiveness, predictive validity, and response-shift effects. Clinical anchors can be used to
assess responsiveness, which is the ability of a PRO measure to detect underlying health status changes over time. A related property is predictive validity, which uses baseline or the change pattern of PROs to predict adverse health events or disease progression, including premature mortality. Response-shift effects capture changes in a patient/survivor’s responses to a PRO measure that reflect shifts in the person’s values, standards, or conceptualization of the PRO and their psychological adaptation during their cancer journey. Without knowing the magnitude of response shift, the comparisons of PRO scores before and after the interventions or disease activities will be biased as will other longitudinal assessments. These time-dependent properties are clinically useful for predicting disease progression, advising preventive interventions, and longitudinal research of PROs.

Many of the extant PRO measures are available in multiple languages. However, few have been extensively cross-culturally validated. Childhood cancer is a rare disease, so clinical trials often need to pool different participants across nations [40]. This requires multiple language translations of the same PRO measure, and cross-cultural validity provides evidence that the items are assessing the same construct in the same way across language translations [26]. The COSMIN guidelines require two groups (e.g., a Chinese-speaking sample and an English-speaking sample) to be compared to establish cross-cultural validity [26]. There are methods for examining the cross-cultural validity both during the development of a PRO measure (e.g., translatability review) and for translation after a PRO measure has been developed in a language, usually English [41] (e.g., linguistic validation). For example, the PROMIS instruments underwent a translatability review in the development of the subjective well-being item pool [42]. Items were modified or removed if the content or sentence structure could not easily be translated into Spanish or German [42]. The practice of translatability assessment is still being refined [41]. Guidelines for the translation of PRO measures have been published by the MAPI Research Institute [43] and the PRO Consortium [44]. Clinicians may consider the original language used to develop a PRO measure and the methods by which other language translations were developed when choosing a PRO measure for their work.

Some limitations of the current study should be noted. We chose to focus our review on the most commonly used existing PRO measures and did not include every PRO measure that is used with pediatric cancer patients and survivors. There are other infrequently used PRO measures that may capture content domains different from the PRO measures reported here. Another limitation is that we only conducted our literature search in PubMed, a database indexing key clinical journals for pediatric oncologists and other clinicians, because we wanted to focus on PRO measures that would be used by these healthcare professionals. PubMed also includes PubMed Central (or PMC), which is a free digital repository that archives open access full-text articles published in biomedical and life sciences journals. Our review was not a systematic review, so it was not our intention to search for articles from all databases. In addition, we limited our search to articles and measures that were available in English, and we excluded articles published only in abstract form and those from grey literature. If we had included non-English and grey literature articles, we may have reviewed a broader scope of literature, but would have had difficulty finding high-quality articles and summarizing our findings [45].

There are many existing generic and cancer-specific measures used with pediatric cancer patients and survivors to assess PROs. However, these measures are varied in their content coverage across physical, psychological, and social domains and limited by their scoring methods and reported measurement properties. As such, there is no single gold standard PRO measure for this population. One set of PRO measures that is most comprehensive is the PROMIS [46]. This generic measure is useful for comparing outcomes of childhood cancer patients with different diagnoses to healthy children or children with other diseases. However, the PROMIS may not be sensitive to detecting changes of PRO scores over time that correspond to changes in underlying health conditions (i.e., lacking in evidence of responsiveness). There is a need for a PRO measure that has both generic items for cross-disease comparison and cancer-specific items that are sensitive to detect
differences among various cancer diagnoses and treatment modalities. To appropriately use PRO measures in pediatric oncology, clinicians and researchers should consider key issues when choosing a PRO measure to use: what is the purpose of using the PRO measure—for classification, prediction, and/or communication with patients? It is also important for clinicians to consider the measurement properties of a PRO measure that support its use in their cancer patient/survivor population for their purpose. Is this measure going to be used over the longitudinal course of a patient’s cancer journey? Is it going to be used as a screening measure? Is it going to be used in a group with a specific diagnosis? Is it going to be used in a multinational group of people who speak different languages? These questions will guide clinicians and researchers to choose the most suitable PRO measures that will best answer their specific questions and meet their specific needs. In the provided tables, we have summarized the characteristics (see Supplementary Table S1), content coverage (see Tables 2 and 3), psychometric properties (see Table 4 and Supplementary Table S2), and language translations (see Supplementary Table S3) of each PRO measure. These summary tables can be used as references for clinicians and researchers to choose a PRO measure that is appropriate for their purpose and population. For example, a researcher may want to include a short, generic PRO measure of symptoms and emotional distress that is available in multiple languages. The tables reveal that the BDI, HUI, PedsQL-Core, and PROMIS all fit these criteria. From this narrowed down list, clinicians and researchers could examine the measurement properties and additional information about each measure and decide which to use in their clinical care or research.

Future research should focus on improving the clinical validity of existing PRO measures and clinical implementation of PRO measures. Before implementation, psychometric properties of the PRO measures must be considered to ensure that PRO measures are appropriately assessing the intended construct in childhood cancer patients. PRO measure implementation in clinical care is beneficial for patient-provider communication, focusing care on issues important to the patient, and providing needed referrals [47–49]. To assist in implementation, a decision tool could be made in future research that addresses the above questions and guides clinicians to choose the most suitable PRO measure for a particular pediatric cancer patient or survivor population and that focuses on the most relevant PRO content and contains appropriate measurement properties. The implementation of PRO measures into clinical care can provide clinicians with evidence of the patient experience that can be used to improve the patient’s HRQOL. Collecting patient-reported symptoms is especially meaningful and clinically actionable, which has shown HRQOL improvement for adult cancer patients [50]. However, the implementation of this strategy is still uncommon in pediatric cancer care and clinical trials [51]. Additionally, PROs related to the patient’s family and relationships (e.g., parenting behavior, family cohesion) are associated with symptom burden and HRQOL in young childhood cancer survivors [52]. This suggests that assessing social domains of PROs may also provide information to clinicians that can be addressed in clinical care to improve HRQOL. Therefore, it is important to conduct routine PRO assessment and monitoring in pediatric cancer care to facilitate clinical decision-making and improve quality of care for these patients.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/children9101497/s1, Supplementary Table S1. Characteristics of PRO measures used in pediatric cancer populations; Supplementary Table S2. Specific research reporting the measurement properties of PRO measures for pediatric cancer populations; Supplementary Table S3. Available language translations of PRO measures for pediatric cancer populations; Supplementary Table S4. Key references for PRO measures included in the present review study for pediatric cancer populations.

**Author Contributions:** Conceptualization, M.R.H. and I.-C.H.; methodology, M.R.H. and I.-C.H.; formal analysis, M.R.H. and J.-a.S.; investigation, M.R.H., J.-a.S. and I.-C.H.; data curation, M.R.H.; writing—original draft preparation, M.R.H.; writing—review and editing, M.R.H., J.N.B. and I.-C.H.; visualization, M.R.H.; supervision, I.-C.H.; project administration, I.-C.H.; funding acquisition, I.-C.H. and K.R.K. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the U.S. National Cancer Institute under award numbers, R01CA238368 (Huang/Baker), and T32CA225590 (Krull). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ward, Z.J.; Yeh, J.M.; Bhakta, N.; Frazier, A.L.; Girardi, F.; Atun, R. Global childhood cancer survival estimates and priority-setting: A simulation-based analysis. *Lancet Oncol.* 2019, 20, 972–983. [CrossRef]

2. Children’s Oncology Group. *Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 5.0,* Children’s Oncology Group: Monrovia, CA, USA, 2018.

3. McDougall, J.; Tsonis, M. Quality of life in survivors of childhood cancer: A systematic review of the literature (2001–2008). *Support Care Cancer* 2009, 17, 1231–1246. [CrossRef] [PubMed]

4. Varni, J.W.; Limbers, C.A.; Burwinkle, T.M. Impaired health-related quality of life in children and adolescents with chronic conditions: A comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. *Health Qual. Life Outcomes* 2007, 5, 43. [CrossRef] [PubMed]

5. Zeltzer, L.K.; Lu, Q.; Leisenring, W.; Tsao, J.C.; Recklitis, C.; Armstrong, G.; Mertens, A.C.; Robison, L.L.; Ness, K.K. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: A report from the Childhood Cancer Survivor Study. *Cancer Epidemiol. Biomark. Prev.* 2008, 17, 435–446. [CrossRef] [PubMed]

6. Bhakta, N.; Liu, Q.; Ness, K.K.; Baassiri, M.; Eissa, H.; Ehrhardt, M.J.; Bass, J.; Bishop, M.W.; et al. The cumulative burden of surviving childhood cancer: An initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet* 2017, 380, 2569–2582. [CrossRef]

7. Wilson, I.B. Linking clinical variables with health-related quality of life. *JAMA* 1995, 273, 59. [CrossRef]

8. U.S. Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; U.S. Food and Drug Administration: Silver Spring, MI, USA, 2009.

9. Berkman, A.M.; Murphy, K.M.; Siembida, E.J.; Lau, N.; Geng, Y.; Parsons, S.K.; Salsman, J.M.; Roth, M.E. Inclusion of patient-reported outcomes in adolescent and young adult phase III therapeutic trials: An analysis of cancer clinical trials registered on ClinicalTrials.gov. *Value Health* 2021, 24, 1820–1827. [CrossRef]

10. Gotay, C.C.; Kawamoto, C.T.; Bottomley, A.; Efficace, F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J. Clin. Oncol.* 2004, 22, 1355–1363. [CrossRef]

11. Huang, J.C.; Ehrhardt, M.; Liu, W.; Li, C.; Mulrooney, D.A.; Chemaitilly, W.; Srivastava, D.K.; Armstrong, G.T.; Robison, L.L.; Hudson, M.M.; et al. Longitudinal symptoms predict future clinically assessed chronic health conditions (CHCs) in adult survivors of childhood cancer: A follow-up study over two decades. In Proceedings of the International Society of Paediatric Oncology (SIOP) Virtual Congress, Virtual Meeting, 14–17 October 2020.

12. Astrup, G.L.; Hofso, K.; Bjordal, K.; Guren, M.G.; Vistad, I.; Cooper, B.; Miaskowski, C.; Rustoen, T. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. *Acta Oncol.* 2017, 56, 462–470. [CrossRef]

13. Miaskowski, C.; Aouizerat, B.E.; Dodd, M.; Cooper, B. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. *J. Natl. Cancer Inst. Monogr.* 2007, 37, 39–46. [CrossRef]

14. Finnegan, L.; Campbell, R.T.; Ferrans, C.E.; Wilbur, J.; Wilkie, D.J.; Shaver, J. Symptom cluster experience profiles in adult survivors of childhood cancers. *J. Pain Symptom Manag.* 2009, 38, 258–269. [CrossRef] [PubMed]

15. Zhou, X.; Mencie, J.; Barabasi, A.-L.; Sharma, A. Human symptoms–disease network. *Nat. Commun.* 2014, 5, 4212. [CrossRef] [PubMed]

16. Dodd, M.J.; Miaskowski, C.; Paul, S.M. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol. Nurs. Forum.* 2001, 28, 465–470. [PubMed]

17. Miaskowski, C.; Barsevick, A.; Berger, A.; Casagrande, R.; Grady, P.A.; Jacobsen, P.; Kuttner, J.; Patrick, D.; Zimmerman, L.; Xiao, C.; et al. Advancing symptom science through symptom cluster research: Expert panel proceedings and recommendations. *J. Natl. Cancer Inst. Am.* 2017, 109, djw253. [CrossRef]

18. Chen, M.; Jones, C.M.; Bauer, H.E.; Osakwe, O.; Ketheeswaran, P.; Baker, J.N.; Huang, I.-C. Barriers and opportunities for patient-reported outcome implementation: A national pediatrician survey in the United States. *Children* 2022, 9, 185. [CrossRef] [PubMed]

19. Hatfield, D.R.; Ogles, B.M. The use of outcome measures by psychologists in clinical practice. *Prof. Psychol. Res. Pract.* 2004, 35, 485–491. [CrossRef]

20. Anthony, S.J.; Selkirk, E.; Sung, L.; Klassen, R.J.; Dix, D.; Scheinemann, K.; Klassen, A.F. Considering quality of life for children with cancer: A systematic review of patient-reported outcome measures and the development of a conceptual model. *Qual. Life Res.* 2014, 23, 771–789. [CrossRef]
21. Chen, P.; Melissa, H.M.; Li, M.; Huang, I.C. Health utilities in pediatric cancer patients and survivors: A systematic review and meta-analysis for clinical implementation. *Qual. Life Res.* 2021, 31, 343–374. [CrossRef]

22. Klassen, A.F.; Strohm, S.J.; Maurice-Stamm, H.; Grotenhuis, M.A. Quality of life questionnaires for children with cancer and childhood cancer survivors: A review of the development of available measures. *Support. Care Cancer* 2010, 18, 1207–1217. [CrossRef]

23. Schulte, F.; Russell, K.B.; Cullen, P.; Embry, L.; Fay-Mcclymont, T.; Johnston, D.; Rosenberg, A.R.; Sung, L. Systematic review and meta-analysis of health-related quality of life in pediatric CNS tumor survivors. *Pediatr. Blood Cancer* 2017, 64, e26442. [CrossRef]

24. Sodergren, S.C.; Husson, O.; Robinson, J.; Rohde, G.E.; Tomaszewksa, I.M.; Vivat, B.; Dyar, R.; Darlington, A.S. Systematic review of the health-related quality of life issues facing adolescents and young adults with cancer. *Qual. Life Res.* 2017, 26, 1659–1672. [CrossRef] [PubMed]

25. Tomlinson, D.; Hinds, P.S.; Etherie, M.C.; Ness, K.K.; Zupanec, S.; Sung, L. Psychometric properties of instruments used to measure fatigue in children and adolescents with cancer: A systematic review. *J. Pain Symptom Manag.* 2013, 45, 83–91. [CrossRef] [PubMed]

26. Prinsen, C.A.C.; Mokkink, L.B.; Bouter, L.M.; Alonso, J.; Patrick, D.L.; De Vet, H.C.W.; Terwee, C.B. COSMIN guideline for systematic reviews of patient-reported outcome measures. *Qual. Life Res.* 2018, 27, 1147–1157. [CrossRef] [PubMed]

27. Mokkink, L.B.; De Vet, H.C.W.; Prinsen, C.A.C.; Patrick, D.L.; Alonso, J.; Bouter, L.M.; Terwee, C.B. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. *Qual. Life Res.* 2018, 27, 1171–1179. [CrossRef] [PubMed]

28. Terwee, C.B.; Prinsen, C.A.C.; Chiarotto, A.; Westernman, M.J.; Patrick, D.L.; Alonso, J.; Bouter, L.M.; De Vet, H.C.W.; Mokkink, L.B. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: A Delphi study. *Qual. Life Res.* 2018, 27, 1159–1170. [CrossRef]

29. Anthony, S.J.; Selkirk, E.; Sung, L.; Klassen, R.J.; Dix, D.; Klassen, A.F. Quality of life of pediatric oncology patients: Do patient-reported outcome instruments measure what matters to patients? *Qual. Life Res.* 2017, 26, 273–281. [CrossRef]

30. Garcia, S.F.; Cella, D.; Clauser, S.B.; Flynn, K.E.; Lad, T.; Lai, J.-S.; Reeve, B.B.; Wilder Smith, A.; Stone, A.A.; Weinfurt, K. Standardizing patient-reported outcomes assessment in cancer clinical trials: A Patient-Reported Outcomes Measurement Information System initiative. *J. Clin. Oncol.* 2007, 25, 5106–5112. [CrossRef]

31. Krabbe, P.F.M.; Van Asselt, A.D.I.; Selivanova, A.; Jabrayilov, R.; Vermeulen, K.M. Patient-centered item selection for a new preference-based generic health status instrument: CS-Base. *Value Health* 2019, 22, 467–473. [CrossRef]

32. McNeish, D.; Wolf, M.G. Thinking twice about sum scores. *Behav. Res. Methods* 2020, 52, 2287–2305. [CrossRef]

33. Stover, A.M.; McLeod, I.D.; Langer, M.M.; Chen, W.-H.; Reeve, B.B.; Wilder Smith, A.; Stone, A.A.; Weinfurt, K. Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale- judgment method. *Qual. Life Res.* 2016, 25, 13–23. [CrossRef] [PubMed]

34. Thissen, D.; Liu, Y.; Magnus, B.; Quin, H.; Gipson, D.S.; Dampier, C.; Huang, I.C.; Hinds, P.S.; Selewski, D.T.; Reeve, B.B.; et al. Chronic conditions and utility-based health-related quality of life in adult childhood cancer survivors. *J. Natl. Cancer Inst.* 2016, 108, djw046. [CrossRef] [PubMed]

35. Mann, C.M.; Schanberg, L.E.; Wang, M.; von Scheven, E.; Lucas, N.; Hernandez, A.; Ringold, S.; Reeve, B.B. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. *Qual. Life Res.* 2020, 29, 2573–2584. [CrossRef]

36. Major, A.; Cox, S.M.; Volchenboum, S.L. Using big data in pediatric oncology: Current applications and future directions. *Semin. Oncol.* 2020, 47, 56–64. [CrossRef]

37. Acquadro, C.; Patrick, D.L.; Eremenco, S.; Martin, M.L.; Kuliš, D.; Correia, H.; Conway, K. Emerging good practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) measures. *J. Patient Rep. Outcomes* 2017, 2, 8. [CrossRef]

38. Ravens-Sieberer, U.; Devine, J.; Bevans, K.; Riley, A.W.; Moon, J.; Salsman, J.M.; Forrest, C.B. Subjective well-being measures for children were developed within the PROMIS project: Presentation of first results. *J. Clin. Epidemiol.* 2014, 67, 207–218. [CrossRef]

39. Acquadro, C.; Conway, K.; Christelle, G.; Mear, I. *Linguistic Validation Manual for Health Outcome Assessments*; Mapi Institute: Downey, CA, USA, 2012.

40. Eremenco, S.; Pease, S.; Mann, S.; Berry, P. Patient-Reported Outcome (PRO) Consortium translation process: Consensus development of updated best practices. *J. Patient Rep. Outcomes* 2017, 2, 12. [CrossRef]

41. Mahood, Q.; Van Eerd, D.; Irvin, E. Searching for grey literature for systematic reviews: Challenges and benefits. *Res. Synth. Methods* 2014, 5, 221–234. [CrossRef] [PubMed]
46. Walsh, T.R.; Irwin, D.E.; Meier, A.; Varni, J.W.; DeWalt, D.A. The use of focus groups in the development of the PROMIS pediatrics item bank. *Qual. Life Res.* 2008, 17, 725–735. [CrossRef] [PubMed]

47. Yang, L.Y.; Manhas, D.S.; Howard, A.F.; Olson, R.A. Patient-reported outcome use in oncology: A systematic review of the impact on patient-clinician communication. *Support Care Cancer* 2018, 26, 41–60. [CrossRef] [PubMed]

48. Nic Giolla Easpaig, B.; Tran, Y.; Bierbaum, M.; Arnolda, G.; Delaney, G.P.; Liauw, W.; Ward, R.L.; Olver, I.; Currow, D.; Girgis, A.; et al. What are the attitudes of health professionals regarding patient reported outcome measures (PROMs) in oncology practice? A mixed-method synthesis of the qualitative evidence. *BMC Health Serv. Res.* 2020, 20, 102. [CrossRef] [PubMed]

49. Schepers, S.A.; Haverman, L.; Zadeh, S.; Grootenhuis, M.A.; Wiener, L. Healthcare professionals’ preferences and perceived barriers for routine assessment of patient-reported outcomes in pediatric oncology practice: Moving toward international processes of change. *Pediatr. Blood Cancer* 2016, 63, 2181–2188. [CrossRef]

50. Basch, E.; Deal, A.M.; Kris, M.G.; Scher, H.I.; Hudis, C.A.; Sabbatini, P.; Rogak, L.; Bennett, A.V.; Dueck, A.C.; Atkinson, T.M.; et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. *J. Clin. Oncol.* 2016, 34, 557–565. [CrossRef]

51. Leahy, A.B.; Feudtner, C.; Basch, E. Symptom monitoring in pediatric oncology using patient-reported outcomes: Why, how, and where next. *Patient* 2018, 11, 147–153. [CrossRef]

52. Huang, I.C.; Brinkman, T.M.; Mullins, L.; Pui, C.-H.; Robison, L.L.; Hudson, M.M.; Krull, K.R. Child symptoms, parent behaviors, and family strain in long-term survivors of childhood acute lymphoblastic leukemia. *Psycho-Oncology* 2018, 27, 2031–2038. [CrossRef]